lifestyle.ukuncut.org.uk

Author: Arcutis Biotherapeutics, Inc.

Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

April 22, 2026
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

April 15, 2026
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

March 31, 2026
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

March 28, 2026
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

March 18, 2026
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

March 10, 2026
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

March 5, 2026
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis

March 3, 2026
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference

February 27, 2026
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026